15:21 , Jul 19, 2018 |  BC Innovations  |  Translation in Brief

Inflammatory images

A University of Calgary team has implicated the inflammasome in acute kidney injury induced by contrast imaging agents and identified targets that could help prevent it. In patients with diminished renal function, such as those...
17:40 , Mar 3, 2017 |  BC Week In Review  |  Financial News

Arch Biopartners completes private placement

Infectious disease and cancer company Arch Biopartners Inc. (TSX-V:ARCH; OTCBB:FOIFF) raised C$400,000 ($305,040) through the sale of 1 million shares at C$0.40 in a non-brokered private placement on Feb. 28. Arch Biopartners Inc. (TSX-V:ARCH; OTCBB:FOIFF),...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Financial News

Arch Biopartners completes private placement of units

Arch Biopartners Inc. (TSX-V:ACH; OTCBB:FOIFF), Toronto, Ontario   Business: Infectious, Cancer   Date completed: 2016-06-23   Type: Private placement of units   Raised: C$330,000 ($257,037)   Units: 660,000   Price: C$0.50 (unit)   Shares after...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Financial News

Arch Biopartners proposes private placement of units

Arch Biopartners Inc. (TSX-V:ACH; OTCBB:FOIFF), Toronto, Ontario   Business: Infectious, Cancer   Date announced: 2016-06-14   Type: Private placement of units   To be raised: Up to C$400,000 ($313,120)   Units: 800,000   Price: C$0.50...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

University of Cincinnati, Arch Biopartners deal

Arch exercised an option to exclusively license AB569 from the university. The university will receive an undisclosed upfront payment and is eligible for milestone payments. Arch expects to begin clinical trials by early 2017. The...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Company News

University of Cincinnati, Arch Biopartners deal

The university granted Arch a one-year option to license exclusive commercial rights to a pending U.S. patent covering a candidate to treat Pseudomonas aeruginosa respiratory infections. Arch plans to start a clinical trial this year...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Financial News

Arch Biopartners completes private placement of units

Arch Biopartners Inc. (CNSX:ACH), Toronto, Ontario   Business: Inflammation, Renal, Cancer   Date completed: 2015-01-06   Type: Private placement of units   Raised: C$750,049 ($636,492)   Units: 2.1 million   Price: C$0.35 (unit)   Shares...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Financial News

Arch Biopartners completes private placement of units

Arch Biopartners Inc. (CNSX:ACH), Toronto, Ontario   Business: Inflammation, Renal, Cancer   Date completed: 2014-08-05   Type: Private placement of units   Raised: C$175,140 ($160,253)   Units: 625,000   Price: C$0.28 (unit)   Shares after...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Financial News

Arch Biopartners Inc completes private placement of units

Arch Biopartners Inc . (CNSX:ACH), Toronto, Ontario   Business: Inflammation, Renal, Cancer   Date completed: 2014-07-07   Type: Private placement of units   Raised: C$200,200 ($187,467)   Units: 715,000   Price: C$0.28 (unit)   Shares...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Arch Biopartners, University of Cincinnati deal

The university granted Arch a one-year option to exclusively license rights to U.S. Patent No. 8,557,300, which covers an approach to treat Pseudomonas aeruginosa respiratory infections using acidified nitrite. During the option period, Arch and...